Ageing perspective on cognitive outcomes from reproductive hormone adjustments
Status PubMed-not-MEDLINE Jazyk angličtina Země Velká Británie, Anglie Médium electronic-ecollection
Typ dokumentu časopisecké články, přehledy
PubMed
37664737
PubMed Central
PMC10470197
DOI
10.1016/j.heliyon.2023.e19050
PII: S2405-8440(23)06258-8
Knihovny.cz E-zdroje
- Klíčová slova
- Cognitive decline, Contraception, Gender transition, Healthy ageing, Hormone replacement therapy, Neuroprotection, Oestrogen, Transgender,
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
In addition to primary reproductive functions, gonadal hormones play an important role in an array of neural mechanisms across the human lifespan. The ageing-related decline in their activity has been linked to the deterioration of cognitive functions in otherwise healthy women, associated with menopause transition, contributing to higher incidents of post-menopause dementia. Given the growing utility of gonadal steroids for birth control, as well as for compensatory treatment of menopause and oophorectomy symptoms, and adjuvant transgender therapy, their long-term effects on neural mechanisms warrant comprehensive assessment. In this article, we present an ageing perspective on the cognitive outcomes from contraceptive and replacement therapeutic use of gonadal hormones and discuss their effects on the risk of developing Alzheimer's and Parkinson's dementia. Despite rising data supporting the ameliorative effects of reproductive hormones on cognitive facilities, their impact varies depending on study design and type of intervention, thus, implying dynamic neuro-endocrine interactions with complex compensatory mechanisms. Elucidating differential effects of reproductive hormone adjustments on cognition with underlying mechanisms is expected not only to shed light on important aspects of brain ageing and dementia but to facilitate their use in personalized medicine with improved safety margins and therapeutic outcomes.
Bader College Herstmonceux Castle Hailsham BN27 1RN United Kingdom
Faculty of Health Sciences Queen's University Kingston Ontario K7L 3N6 Canada
Zobrazit více v PubMed
Brayne C., Miller B. Dementia and aging populations-A global priority for contextualized research and health policy. PLoS Med. 2017;14(3) PubMed PMC
Collaborators G.B.D.D.F. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105–e125. PubMed PMC
Gurvich C., et al. Sex hormones and cognition in aging. Vitam. Horm. 2021;115:511–533. PubMed
Gurvich C., Thomas N., Kulkarni J. Sex differences in cognition and aging and the influence of sex hormones. Handb. Clin. Neurol. 2020;175:103–115. PubMed
Bowman R., Frankfurt M., Luine V. Sex differences in cognition following variations in endocrine status. Learn. Mem. 2022;29(9):234–245. PubMed PMC
Luine V.N. Sex steroids and cognitive function. J. Neuroendocrinol. 2008;20(6):866–872. PubMed
Marrocco J., McEwen B.S. Sex in the brain: hormones and sex differences. Dialogues Clin. Neurosci. 2016;18(4):373–383. PubMed PMC
Androvicova R., Pfaus J.G., Ovsepian S.V. Estrogen pendulum in schizophrenia and Alzheimer's disease: review of therapeutic benefits and outstanding questions. Neurosci. Lett. 2021;759 PubMed
Fester L., Rune G.M. Sex neurosteroids: hormones made by the brain for the brain. Neurosci. Lett. 2021;753 PubMed
Singh S., Fereshetyan K., Shorter S., Paliokha R., Dremencov E., Yenkoyan K., Ovsepian S.V. Brain-derived neurotrophic factor (BDNF) in perinatal depression: side show or pivotal factor? Drug Discov. Today. 2023;28(2):103467. doi: 10.1016/j.drudis.2022.103467. Epub 2022 Dec 14. PMID: 36528281. PubMed DOI
Walker W.H. Testosterone signaling and the regulation of spermatogenesis. Spermatogenesis. 2011;1(2):116–120. PubMed PMC
Walker W.H. Androgen actions in the testis and the regulation of spermatogenesis. Adv. Exp. Med. Biol. 2021;1288:175–203. PubMed
Fuentes N., Silveyra P. Estrogen receptor signaling mechanisms. Adv. Prot. Chem. Struc. Biol. 2019;116:135–170. PubMed PMC
McEwen B.S., Milner T.A. Understanding the broad influence of sex hormones and sex differences in the brain. J. Neurosci. Res. 2017;95(1–2):24–39. PubMed PMC
Hara Y., et al. Estrogen effects on cognitive and synaptic health over the lifecourse. Physiol. Rev. 2015;95(3):785–807. PubMed PMC
Hogervorst E., et al. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000;101(3):485–512. PubMed
Núñez F., Maraver M.J., Colzato L.S. Sex hormones as cognitive enhancers? J. Cogn. Enhan. 2020;4:228–233.
Wolf O.T. Cognitive functions and sex steroids. Ann. Endocrinol. 2003;64(2):158–161. PubMed
Adams M.M., et al. Estrogen and aging affect the subcellular distribution of estrogen receptor-alpha in the hippocampus of female rats. J. Neurosci. 2002;22(9):3608–3614. PubMed PMC
Maioli S., et al. Estrogen receptors and the aging brain. Essays Biochem. 2021;65(6):913–925. PubMed PMC
Maki P.M., Henderson V.W. Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on. Climacteric. 2012;15(3):256–262. PubMed PMC
Nebel R.A., et al. Understanding the impact of sex and gender in Alzheimer's disease: a call to action. Alzheimers Dement. 2018;14(9):1171–1183. PubMed PMC
Vinogradova Y., et al. Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases. BMJ. 2021;374:n2182. PubMed PMC
Conde D.M., et al. Menopause and cognitive impairment: a narrative review of current knowledge. World J. Psychiatr. 2021;11(8):412–428. PubMed PMC
Sudhakar D., et al. Neurourol Urodyn; 2022. Feminizing Gender-Affirming Hormone Therapy for the Transgender and Gender Diverse Population: an Overview of Treatment Modality, Monitoring, and Risks. PubMed
T'Sjoen G., et al. European society for sexual medicine position statement "assessment and hormonal management in adolescent and adult trans people, with attention for sexual function and satisfaction". J. Sex. Med. 2020;17(4):570–584. PubMed
Narayan S.K., et al. Gender confirmation surgery for the endocrinologist. Endocrinol Metab. Clin. N. Am. 2019;48(2):403–420. PubMed
Lobo R.A. Hormone-replacement therapy: current thinking. Nat. Rev. Endocrinol. 2017;13(4):220–231. PubMed
Song X., et al. Reproductive and hormonal factors and risk of cognitive impairment among Singapore Chinese women. Am. J. Obstet. Gynecol. 2020;223(3):410 e1–e410 e23. PubMed PMC
Gong J., et al. Reproductive factors and the risk of incident dementia: a cohort study of UK Biobank participants. PLoS Med. 2022;19(4) PubMed PMC
Egan K.R., Gleason C.E. Longer duration of hormonal contraceptive use predicts better cognitive outcomes later in life. J. Womens Heal. 2012;21(12):1259–1266. PubMed PMC
Bronnick M.K., et al. The effects of hormonal contraceptives on the brain: a systematic review of neuroimaging studies. Front. Psychol. 2020;11 PubMed PMC
Shumaker S.A., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289(20):2651–2662. PubMed
Henderson V.W., et al. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. J. Neurol. Neurosurg. Psychiatry. 2005;76(1):103–105. PubMed PMC
Savolainen-Peltonen H., et al. Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. BMJ. 2019;364:l665. PubMed PMC
Imtiaz B., et al. Risk of Alzheimer's disease among users of postmenopausal hormone therapy: a nationwide case-control study. Maturitas. 2017;98:7–13. PubMed
Imtiaz B., et al. Postmenopausal hormone therapy and Alzheimer disease: a prospective cohort study. Neurology. 2017;88(11):1062–1068. PubMed PMC
Wu M., et al. Postmenopausal hormone therapy and Alzheimer's disease, dementia, and Parkinson's disease: a systematic review and time-response meta-analysis. Pharmacol. Res. 2020;155 PubMed
LeBlanc E.S., et al. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001;285(11):1489–1499. PubMed
Harman S.M., et al. KEEPS: the kronos early estrogen prevention study. Climacteric. 2005;8(1):3–12. PubMed
Miller V.M., et al. The kronos early estrogen prevention study (KEEPS): what have we learned? Menopause. 2019;26(9):1071–1084. PubMed PMC
Song Y.J., et al. The effect of estrogen replacement therapy on alzheimer's disease and Parkinson's disease in postmenopausal women: a meta-analysis. Front. Neurosci. 2020;14:157. PubMed PMC
Henderson V.W., et al. Cognition, mood, and physiological concentrations of sex hormones in the early and late postmenopause. Proc. Natl. Acad. Sci. U.S.A. 2013;110(50):20290–20295. PubMed PMC
Chen Y.C., et al. Risk assessment of dementia after hysterectomy: analysis of 14-year data from the national health insurance research database in taiwan. J. Chin. Med. Assoc. 2020;83(4):394–399. PubMed
Imtiaz B., et al. Oophorectomy, hysterectomy, and risk of Alzheimer's disease: a nationwide case-control study. J. Alzheimers Dis. 2014;42(2):575–581. PubMed
Rocca W.A., et al. Hysterectomy, oophorectomy, estrogen, and the risk of dementia. Neurodegener. Dis. 2012;10(1–4):175–178. PubMed PMC
Gilsanz P., et al. Reproductive period and risk of dementia in a diverse cohort of health care members. Neurology. 2019;92(17):e2005–e2014. PubMed PMC
Auer M.K., et al. Transgender transitioning and change of self-reported sexual orientation. PLoS One. 2014;9(10) PubMed PMC
Murad M.H., et al. Hormonal therapy and sex reassignment: a systematic review and meta-analysis of quality of life and psychosocial outcomes. Clin. Endocrinol. 2010;72(2):214–231. PubMed
Unger C.A. Hormone therapy for transgender patients. Transl. Androl. Urol. 2016;5(6):877–884. PubMed PMC
van Heesewijk J.O., et al. Long-term gender-affirming hormone therapy and cognitive functioning in older transgender women compared with cisgender women and men. J. Sex. Med. 2021;18(8):1434–1443. PubMed
Cicero E., Flatt J., W W. Transgender adults report greater cognitive and related functional challenges: findings from the 2015-2019 Behavioral Risk Factor Surveillance System. Alzheimer's Dementia. 2021;17(Suppl. 10)
Lambrou N.H., et al. Prevalence of modifiable risk factors for Alzheimer's disease and related dementias, and association with cognitive disability among transgender and gender non-binary adults in the U.S.: BRFSS 2019. Alzheimer's Dementia. 2021;17(Suppl. 10) 2021.